



Material Safety Data Sheet Cover-Sheet – This page provides additional New Zealand specific information for this product and must be read in conjunction with the Safety Data Sheet (SDS) attached

Product Name: Stela Automix, Stela Capsule

Manufacturer: SDI Limited

SDS Expiry: 5 July 2027

Supplier Details: Henry Schein New Zealand

243-249 Bush Road, Rosedale, Auckland, 0632 PO Box 101 140, North Shore, Auckland 0745

Ph. 0800 808 855

www.henryschein.co.nz

Emergency Contacts: Poisons/Hazardous Chemical Info Centre –

0800POISON/0800764766 (24 Hours) Phone 111 for Fire, Ambulance or Police

HSNO Class/Category: 6

HSNO Group Standard: Dental Products Subsidiary Hazard Group Standard 2020

HSR002558

Statements/Pictograms: As per attached Safety Data Sheet (SDS)

Date Prepared: This coversheet was prepared – September 2023

This SDS coversheet has been produced by Henry Schein NZ and has been prepared in accordance with NZ EPA advice on making overseas SDS compliant to HSNO Act. The above information is based on the present state of our knowledge of the product at the time of publication. It is given in good faith, no warranty is implied with respect to the quality or the specifications of the product. Users must satisfy that the product is entirely suitable for their purpose. The SDS and this coversheet may be revised from time to time, please ensure you have a current copy.





Stela Automix, Stela Capsule

SDI Limited

Version No: 2.1

Safety Data Sheet (Conforms to Annex II of REACH (1907/2006) - Regulation 2020/878)

Issue Date: **05/07/2022** Print Date: **15/07/2022** L.REACH.GB-NIR.EN.E

SECTION 1 Identification of the substance / mixture and of the company / undertaking

1.1. Product Identifier

Product name	Stela Automix, Stela Capsule		
Chemical Name	Not Applicable		
Synonyms	Not Available		
Chemical formula	Not Applicable		
Other means of identification	Not Available		

1.2. Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Professional dental use: For filling of cavitated teeth by dental professionals.	
Uses advised against	Not Applicable	

1.3. Details of the supplier of the safety data sheet

Registered company name	SDI Limited
Address	3-15 Brunsdon Street Bayswater VIC 3153 Australia
Telephone	+61 3 8727 7111 (Business Hours)
Fax	+61 3 8727 7222
Website	www.sdi.com.au
Email	info@sdi.com.au

1.4. Emergency telephone number

Association / Organisation	SDI Limited	
Emergency telephone numbers	+61 3 8727 7111	
Other emergency telephone numbers	ray.cahill@sdi.com.au	

SECTION 2 Hazards identification

2.1. Classification of the substance or mixture

Classification according to regulation (EC) No 1272/2008 [CLP] and amendments [1]	H315 - Skin Corrosion/Irritation Category 2, H317 - Sensitisation (Skin) Category 1, H319 - Serious Eye Damage/Eye Irritation Category 2, H335 - Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3
Legend:	1. Classification by vendor; 2. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI

2.2. Label elements

Hazard pictogram(s)



Signal word	Warnin

Hazard statement(s)

H315	Causes skin irritation.	
H317	May cause an allergic skin reaction.	
H319	Causes serious eye irritation.	
H335	May cause respiratory irritation.	

Supplementary statement(s)

Version No: 2.1 Page 2 of 16 Issue Date: 05/07/2022 Print Date: 15/07/2022

Stela Automix, Stela Capsule

Precautionary statement(s) Prevention

P271	Use only a well-ventilated area.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P261	Avoid breathing mist/vapours/spray.
P264	Wash all exposed external body areas thoroughly after handling.
P272	Contaminated work clothing should not be allowed out of the workplace.

Precautionary statement(s) Response

IF ON SKIN: Wash with plenty of water and soap.		
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.		
Call a POISON CENTER/doctor/physician/first aider/if you feel unwell.		
If skin irritation or rash occurs: Get medical advice/attention.		
If eye irritation persists: Get medical advice/attention.		
Take off contaminated clothing and wash it before reuse.		
IF INHALED: Remove person to fresh air and keep comfortable for breathing.		

Precautionary statement(s) Storage

P405	Store locked up.
P403+P233	Store in a well-ventilated place. Keep container tightly closed.

Precautionary statement(s) Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

2.3. Other hazards

Ingestion may produce health damage*.

Cumulative effects may result following exposure*.

Limited evidence of a carcinogenic effect*.

Possible respiratory sensitizer*.

Vapours potentially cause drowsiness and dizziness*.

REACH - Art.57-59: The mixture does not contain Substances of Very High Concern (SVHC) at the SDS print date.

Not Applicable

SECTION 3 Composition / information on ingredients

3.1.Substances

See 'Composition on ingredients' in Section 3.2

3.2.Mixtures

1.CAS No 2.EC No 3.Index No 4.REACH No	%[weight]	Name	Classification according to regulation (EC) No 1272/2008 [CLP] and amendments	SCL / M-Factor	Nanoform Particle Characteristics
1.72869-86-4 2.276-957-5 3.616-087-00-9 4.Not Available	10-25	diurethane dimethacrylate	Serious Eye Damage/Eye Irritation Category 2, Sensitisation (Skin) Category 1, Hazardous to the Aquatic Environment Long-Term Hazard Category 2; H319, H317, H411 [2]	Not Available	Not Available
1.1830-78-0 2.217-388-4 3.Not Available 4.Not Available	5-15	glycerol dimethacrylate	Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3; H315, H319, H335 ^[1]	Not Available	Not Available
1.13760-80-0 2.237-354-2 3.Not Available 4.Not Available	3-7	ytterbium(III) fluoride *	Acute Toxicity (Oral, Dermal and Inhalation) Category 4, Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3; H302+H312+H332, H315, H319, H335 [1]	Not Available	Not Available
1.85590-00-7 2.Not Available 3.Not Available 4.Not Available	1-5	10-methacryloyloxydecyl dihydrogen phosphate	Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2, Sensitisation (Skin) Category 1, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3, Hazardous to the Aquatic Environment Long-Term Hazard Category 4; H315, H319, H317, H335, H413 [1]	Not Available	Not Available

SECTION 4 First aid measures

Version No: 2.1 Page 3 of 16 Issue Date: 05/07/2022

Stela Automix, Stela Capsule

Print Date: 15/07/2022

4.1. Description of first aid measures

Eye Contact	If this product comes in contact with the eyes: Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.
Inhalation	 If fumes or combustion products are inhaled remove from contaminated area. Lay patient down. Keep warm and rested. Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. Transport to hospital, or doctor, without delay.
Ingestion	 For advice, contact a Poisons Information Centre or a doctor at once. Urgent hospital treatment is likely to be needed. If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Transport to hospital or doctor without delay.

4.2 Most important symptoms and effects, both acute and delayed

See Section 11

4.3. Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5 Firefighting measures

5.1. Extinguishing media

- ▶ Foam
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.
- Water spray or fog Large fires only.

5.2. Special hazards arising from the substrate or mixture

Fire Incompatibility ▶ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result

5.3. Advice for firefighters

- Alert Fire Brigade and tell them location and nature of hazard.
- May be violently or explosively reactive.
- Wear full body protective clothing with breathing apparatus.
- Prevent, by any means available, spillage from entering drains or water course.
- Fight fire from a safe distance, with adequate cover.
- If safe, switch off electrical equipment until vapour fire hazard removed.
- Use water delivered as a fine spray to control the fire and cool adjacent area.
- Avoid spraying water onto liquid pools.
- Do not approach containers suspected to be hot. Fire Fighting
 - Cool fire exposed containers with water spray from a protected location.
 - If safe to do so, remove containers from path of fire.
 - Alert Fire Brigade and tell them location and nature of hazard.
 - Wear breathing apparatus plus protective gloves.
 - ▶ Prevent, by any means available, spillage from entering drains or water courses. Use water delivered as a fine spray to control fire and cool adjacent area.
 - ▶ DO NOT approach containers suspected to be hot.
 - Cool fire exposed containers with water spray from a protected location.
 - If safe to do so, remove containers from path of fire.
 - Equipment should be thoroughly decontaminated after use.

Combustible.

- Slight fire hazard when exposed to heat or flame.
- ▶ Heating may cause expansion or decomposition leading to violent rupture of containers.
- ▶ On combustion, may emit toxic fumes of carbon monoxide (CO).
- May emit acrid smoke.
- Mists containing combustible materials may be explosive.

Fire/Explosion Hazard

Combustion products include: carbon dioxide (CO2)

nitrogen oxides (NOx)

metal oxides other pyrolysis products typical of burning organic material.

May emit clouds of acrid smoke

May emit poisonous fumes. May emit corrosive fumes

Version No: **2.1** Page **4** of **16** Issue Date: **05/07/2022**

Stela Automix, Stela Capsule

Print Date: 15/07/2022

SECTION 6 Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

See section 8

6.2. Environmental precautions

See section 12

6.3. Methods and material for containment and cleaning up

6.3. Methods and material for C	ontainment and cleaning up
Minor Spills	 Clean up all spills immediately. Avoid contact with skin and eyes. Wear impervious gloves and safety goggles. Trowel up/scrape up. Place spilled material in clean, dry, sealed container. Flush spill area with water.
Major Spills	 Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves. Prevent, by any means available, spillage from entering drains or water course. Stop leak if safe to do so. Contain spill with sand, earth or vermiculite. Collect recoverable product into labelled containers for recycling. Neutralise/decontaminate residue (see Section 13 for specific agent). Collect solid residues and seal in labelled drums for disposal. Wash area and prevent runoff into drains. After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. If contamination of drains or waterways occurs, advise emergency services. DO NOT touch the spill material

6.4. Reference to other sections

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

7.1. Precautions for safe handling

- Most acrylic monomers have low viscosity therefore pouring, material transfer and processing of these materials do not necessitate heating.
- Viscous monomers may require heating to facilitate handling. To facilitate product transfer from original containers, product must be heated to no more than 60 deg. C. (140 F.), for not more than 24 hours.
- ▶ Do NOT use localised heat sources such as band heaters to heat/ melt product.
- Do NOT use steam
- Hot boxes or hot rooms are recommended for heating/ melting material. The hot box or hot room should be set a maximum temperature of 60 deg. C. (140 F.).
- Do NOT overheat this may compromise product quality and /or result in an uncontrolled hazardous polymerisation.
- If product freezes, heat as indicated above and mix gently to redistribute the inhibitor. Product should be consumed in its entirety after heating/ melting; avoid multiple "reheats" which may affect product quality or result in product degradation.
- Product should be packaged with inhibitor(s). Unless inhibited, product may polymerise, raising temperature and pressure, possibly rupturing container. Check inhibitor level periodically, adding to bulk material if needed. In addition, the product's inhibitor(s) require the presence of dissolved oxygen. Maintain, at a minimum, the original headspace in the product container and do NOT blanket or mix with oxygen-free gas as it renders the inhibitor ineffective. Ensure air space (oxygen) is present during product heating / melting.
- Store product indoors at temperatures greater than the product's freeing point (or greater than 0 deg. C. (32 F).) if no freezing point available and below 38 deg. C (100 F.).
- Avoid prolonged storage (longer than shelf-life) storage temperatures above 38 deg. C (100 F.).
 - Store in tightly closed containers in a properly vented storage area away from heat, sparks, open flame, strong oxidisers, radiation and other initiators.
 - Prevent contamination by foreign materials.
 - ▶ Prevent moisture contact
 - Use only non-sparking tools and limit storage time. Unless specified elsewhere, shelf-life is 6 months from receipt.
 - Avoid all personal contact, including inhalation.
 - Wear protective clothing when risk of exposure occurs.
 - Use in a well-ventilated area.
 - Prevent concentration in hollows and sumps.
 - DO NOT enter confined spaces until atmosphere has been checked.
 - DO NOT allow material to contact humans, exposed food or food utensils.
 - Avoid contact with incompatible materials.
 - When handling, **DO NOT** eat, drink or smoke.
 - Keep containers securely sealed when not in use.
 - Avoid physical damage to containers.
 - Always wash hands with soap and water after handling.
 - Work clothes should be laundered separately. Launder contaminated clothing before re-use.
 - Use good occupational work practice.
 - Observe manufacturer's storage and handling recommendations contained within this SDS.
 - Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.

Fire and explosion protection

See section 5

▶ Polymerisation may occur slowly at room temperature.

- Storage requires stabilising inhibitor content and dissolved oxygen content to be monitored. Refer to manufacturer's recommended levels.
- DO NOT overfill containers so as to maintain free head space above product.
 Blanketing or sparging with nitrogen or oxygen free gas will deactivate stabiliser.

Other information

Safe handling

- Store below 38 deg. C.
- Store in original containers.
- Keep containers securely sealed.
- No smoking, naked lights or ignition sources.

Version No: **2.1** Page **5** of **16** Issue Date: **05/07/2022**

Stela Automix, Stela Capsule

Print Date: 15/07/2022

- Store in a cool, dry, well-ventilated area.
- Store away from incompatible materials and foodstuff containers.
- Protect containers against physical damage and check regularly for leaks.
- Observe manufacturer's storage and handling recommendations contained within this SDS.

7.2. Conditions for safe storage, including any incompatibilities

Suitable container

- Metal can or drum
- Packaging as recommended by manufacturer.
- Check all containers are clearly labelled and free from leaks.

for multifunctional acrylates

- Avoid exposure to free radical initiators (peroxides, persulfates), iron, rust, oxidisers, and strong acids and strong bases.
 - Avoid heat, flame, sunlight, X-rays or ultra-violet radiation.
- Storage beyond expiration date, may initiate polymerisation. Polymerisation of large quantities may be violent (even explosive)
- Avoid reaction with water, alcohols and detergent solutions. Isocyanates are electrophiles, and as such they are reactive toward a variety of nucleophiles including alcohols, amines, and even water. Upon treatment with an alcohol, an isocyanate forms a urethane linkage. If a di-isocyanate is treated with a compound containing two or more hydroxyl groups, such as a diol or a polyol, polymer chains are formed, which are known as polyurethanes. Reaction between a di-isocyanate and a compound containing two or more amine groups, produces long polymer chains known as polyureas.
- · Isocyanates and thioisocyanates are incompatible with many classes of compounds, reacting exothermically to release toxic gases. Reactions with amines, strong bases, aldehydes, alcohols, alkali metals, ketones, mercaptans, strong oxidisers, hydrides, phenols, and peroxides can cause vigorous releases of heat. Acids and bases initiate polymerisation reactions in these materials.
- · Isocyanates also can react with themselves. Aliphatic di-isocyanates can form trimers, which are structurally related to cyanuric acid. Isocyanates participate in Diels-Alder reactions, functioning as dienophiles
- Isocyanates easily form adducts with carbodiimides, isothiocyanates, ketenes, or with substrates containing activated CC or CN bonds.
- · Some isocyanates react with water to form amines and liberate carbon dioxide. This reaction may also generate large volumes of foam and heat. Foaming spaces may produce pressure in confined spaces or containers. Gas generation may pressurise drums to the point of rupture. · Do NOT reseal container if contamination is expected

Storage incompatibility

- · Open all containers with care
- · Base-catalysed reactions of isocyanates with alcohols should be carried out in inert solvents. Such reactions in the absence of solvents often occur with explosive violence,
- \cdot Isocyanates will attack and embrittle some plastics and rubbers.
- · The isocyanate anion is a pseudohalide (syn pseudohalogen) whose chemistry, resembling that of the true halogens, allows it to substitute for halogens in several classes of chemical compounds.. The behavior and chemical properties of the several pseudohalides are identical to that of the true halide ions.
- ▶ Stable under controlled storage conditions provided material contains adequate stabiliser / polymerisation inhibitor.
- ▶ Bulk storages may have special storage requirements
- WARNING: Gradual decomposition in strong, sealed containers may lead to a large pressure build-up and subsequent explosion. Rapid and violent polymerisation possible at temperatures above 32 deg c.
- A range of exothermic decomposition energies for isocyanates is given as 20-30 kJ/mol.
- The relationship between energy of decomposition and processing hazards has been the subject of discussion; it is suggested that values of energy released per unit of mass, rather than on a molar basis (J/g) be used in the assessment.
- For example, in "open vessel processes" (with man-hole size openings, in an industrial setting), substances with exothermic decomposition energies below 500 J/g are unlikely to present a danger, whilst those in "closed vessel processes" (opening is a safety valve or bursting disk) present some danger where the decomposition energy exceeds 150 J/g.

BRETHERICK: Handbook of Reactive Chemical Hazards, 4th Edition

7.3. Specific end use(s)

See section 1.2

SECTION 8 Exposure controls / personal protection

8.1. Control parameters

Ingredient	DNELs Exposure Pattern Worker	PNECs Compartment
diurethane dimethacrylate	Dermal 1.3 mg/kg bw/day (Systemic, Chronic) Inhalation 3.3 mg/m³ (Systemic, Chronic) Dermal 0.7 mg/kg bw/day (Systemic, Chronic) * Inhalation 0.6 mg/m³ (Systemic, Chronic) * Oral 0.3 mg/kg bw/day (Systemic, Chronic) *	0.01 mg/L (Water (Fresh)) 0.001 mg/L (Water - Intermittent release) 0.1 mg/L (Water (Marine)) 0.851 mg/kg sediment dw (Sediment (Fresh Water)) 0.46 mg/kg sediment dw (Sediment (Marine)) 0.167 mg/kg soil dw (Soil) 1 mg/L (STP)

^{*} Values for General Population

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
EU Consolidated List of Indicative Occupational Exposure Limit Values (IOELVs)	ytterbium(III) fluoride	Inorganic Fluorides	2.5 mg/m3	Not Available	Not Available	Skin
UK Workplace Exposure Limits (WELs)	ytterbium(III) fluoride	Fluoride (inorganic as F)	2.5 mg/m3	Not Available	Not Available	Not Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
diurethane dimethacrylate	120 mg/m3	1,300 mg/m3	7,900 mg/m3
ytterbium(III) fluoride	30 mg/m3	330 mg/m3	2,000 mg/m3

Ingredient Original IDLH Revised IDLH

Version No: 2.1 Issue Date: 05/07/2022 Page 6 of 16 Print Date: 15/07/2022

Stela Automix, Stela Capsule

Ingredient	Original IDLH	Revised IDLH
diurethane dimethacrylate	Not Available	Not Available
glycerol dimethacrylate	Not Available	Not Available
ytterbium(III) fluoride	Not Available	Not Available
10-methacryloyloxydecyl dihydrogen phosphate	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
diurethane dimethacrylate	E	≤ 0.1 ppm
glycerol dimethacrylate	E	≤ 0.1 ppm
10-methacryloyloxydecyl dihydrogen phosphate	E	≤ 0.1 ppm
Notes:	Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to range of exposure concentrations that are expected to protect worker health	

MATERIAL DATA

8.2. Exposure controls

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection. The basic types of engineering controls are:

Process controls which involve changing the way a job activity or process is done to reduce the risk.

Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.

Employers may need to use multiple types of controls to prevent employee overexposure.

Local exhaust ventilation usually required. If risk of overexposure exists, wear approved respirator. Correct fit is essential to obtain adequate protection. Supplied-air type respirator may be required in special circumstances. Correct fit is essential to ensure adequate protection. An approved self contained breathing apparatus (SCBA) may be required in some situations.

Provide adequate ventilation in warehouse or closed storage area. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapours, degreasing etc., evaporating from tank (in still air).	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)

8.2.1. Appropriate engineering controls

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used

8.2.2. Personal protection









- Safety glasses with side shields.
- Chemical goggles.
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]

Eve and face protection

See Hand protection below Skin protection

Hands/feet protection

NOTE:

The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.

Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.

Version No: 2.1 Page **7** of **16** Issue Date: 05/07/2022 Print Date: 15/07/2022

Stela Automix, Stela Capsule

General warning: Do NOT use latex gloves! Use only recommended gloves - using the wrong gloves may increase the risk: Use of thin nitrile rubber gloves: **Exposure condition** Nitrile rubber (0.1 mm) Short time use; (few minutes less than 0.5 Excellent tactibility ("feel"), powder-free hour) Disposable Little physical stress Inexpensive Give adequate protection to low molecular weigh acrylic monomers Use of medium thick nitrile rubber gloves Nitrile rubber, NRL (latex) free; <0.45 mm **Exposure condition** Moderate tactibility ("feel"), powder-free Medium time use Disposable less than 4 hours Moderate price Physical stress (opening drums, using tools, Gives adequate protection for most acrylates up to 4 hours etc.) Do NOT give adequate protection to low molecular weight monomers at exposures longer than 1 hour Nitrile rubber, NRL (latex) free; >0.56 mm low tactibility ("feel"), powder free High price Exposure condition Gives adequate protection for most acrylates in combination with commonly used solvents Long time up to 8 hours Cleaning operations Do NOT give adequate protection to low molecular weight monomers at exposures longer than 1 hour Avoid use of ketones and acetates in wash-up solutions. Where none of this gloves ensure safe handling (for example in long term handling of acrylates containing high levels of acetates and/ or ketones, use laminated multilayer gloves. Guide to the Classification and Labelling of UV/EB Acrylates Third edition, 231 October 2007 - Cefic Isocyanate resistant materials include Teflon, Viton, nitrile rubber and some PVA gloves. ▶ Protective gloves and overalls should be worn as specified in the appropriate national standard. Contaminated garments should be removed promptly and should not be re-used until they have been decontaminated. ▶ NOTE: Natural rubber, neoprene, PVC can be affected by isocyanates **Body protection** See Other protection below Overalls. P.V.C apron. Barrier cream. Other protection Skin cleansing cream.

Respiratory protection

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

► Eye wash unit.

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	A-AUS P2	-	A-PAPR-AUS / Class 1 P2
up to 50 x ES	-	A-AUS / Class 1 P2	-
up to 100 x ES	-	A-2 P2	A-PAPR-2 P2 ^

^{^ -} Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

8.2.3. Environmental exposure controls

See section 12

SECTION 9 Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance	Tooth coloured viscous flowable paste; does not mix with water.		
Physical state	Free-flowing Paste	Relative density (Water = 1)	Not Available
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Applicable	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Available	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Available	Oxidising properties	Not Available

 Version No: 2.1
 Page 8 of 16
 Issue Date: 05/07/2022

 Print Date: 15/07/2022
 Print Date: 15/07/2022

Stela Automix, Stela Capsule

Surface Tension (dyn/cm or Not Available Not Available Upper Explosive Limit (%) mN/m) Lower Explosive Limit (%) Not Available Volatile Component (%vol) Not Available Vapour pressure (kPa) Not Available Gas group Not Available pH as a solution (Not Solubility in water Not Applicable Immiscible Available%) Vapour density (Air = 1) Not Available VOC a/L Not Available **Nanoform Particle** Nanoform Solubility Not Available Not Available Characteristics

9.2. Other information

Not Available

SECTION 10 Stability and reactivity

Particle Size

Not Available

10.1.Reactivity	See section 7.2
10.2. Chemical stability	 Stable under controlled storage conditions provided material contains adequate stabiliser / polymerisation inhibitor. Bulk storages may have special storage requirements WARNING: Gradual decomposition in strong, sealed containers may lead to a large pressure build-up and subsequent explosion. Rapid and violent polymerisation possible at temperatures above 32 deg c. Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur.
10.3. Possibility of hazardous reactions	See section 7.2
10.4. Conditions to avoid	See section 7.2
10.5. Incompatible materials	See section 7.2
10.6. Hazardous decomposition products	See section 5.3

SECTION 11 Toxicological information

11.1. Information on toxicological effects

Inhaled

Evidence shows, or practical experience predicts, that the material produces irritation of the respiratory system, in a substantial number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system.

Inhalation of vapours may cause drowsiness and dizziness. This may be accompanied by narcosis, reduced alertness, loss of reflexes, lack of coordination and vertigo.

No report of respiratory illness in humans as a result of exposure to multifunctional acrylates has been found. Similarly evidence of systemic damage does not appear to exist.

Inhalation hazard is increased at higher temperatures.

The toxicology of rare earth metal oxides has been determined by pathological and biochemical examination of rodents exposed to the oxides by oral, intraperitoneal or endotracheal routes. Weakly expressed general toxic action of the oxides is seen in acute and prolonged exposure. The dusts cause pronounced changes in the lungs. (The oxides of the rare earth metals are significantly less toxic than their salts.) Symptoms of exposure to rare earth oxides are coughing, congestion, granuloma in lungs and haemoglobinaemia.

Rare earths may cause impairment of blood clotting.

Exposure to rare earth oxide vapours has been reported to result in sensitivity to heat, itching, and an increased awareness of odour and taste, bronchiolitis, sub-acute bronchiolitis (inflammation of the bronchial tubes), acute transient chemical pneumonitis (inflammation of the lungs caused by chemical irritation), focal hypertrophia (excessive development of an organ), emphysema, regional bronchiolar stricturing, cellular eosinophilia (abnormal increase in the number of leucocytes with cytoplasmic inclusions, in the blood that is characteristic of allergic reactions), and, in some cases, fatal delayed chemical hyperemia (excess of blood in a body part).

Intratracheal administration to animals of some rare earth oxides, has been reported to cause changes ranging from mild to marked fibrosis (a condition marked by the increase of interstitial fibrous tissue), emphysema (a condition of the lungs marked by abnormal dilation of the its air spaces and distension of its walls), small white nodules, granulomas (a mass or nodule of chronically inflamed tissue with granulations that are generally associated with an infective process), giant cells, and accumulation of dust in the lungs.

In rare fatal cases of exposure to the rare-earth fluoride and/or oxide mixtures, delayed chemical hyperaemia has occurred. Lung granulomas have also been seen in experimental animals.

Acute effects from inhalation of high vapour concentrations may be chest and nasal irritation with coughing, sneezing, headache and even nausea.

Ingestion Accidental ingestion of the material may be damaging to the health of the individual.

Claim Comton

Evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis.

Skin Contact
The material may accentuate any pre-existing dermatitis condition

All multifunctional acrylates (MFA) produce skin discomfort and are known or suspected skin sensitisers. Aerosols generated in the industrial process are reported to produce dermatitis - vapours generated by the heat of milling may also occur in sufficient concentration to produce dermatitis. Because exposure to industrial aerosols of MFA may also include exposure to various resin systems, photo-initiators, solvents, hydrogen-transfer agents, stabilisers, surfactants, fillers and polymerisation inhibitors, toxic effects may arise due to a range of chemical actions. Open cuts, abraded or irritated skin should not be exposed to this material

Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects.

Version No: 2.1 Page 9 of 16 Issue Date: 05/07/2022

Stela Automix, Stela Capsule

Print Date: 15/07/2022

Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

Eye

Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.

Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems. Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals.

Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to become hyper-responsive.

Substances than can cuase occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances are not classified as asthmagens or respiratory sensitisers Wherever it is reasonably practicable, exposure to substances that can cuase occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive.

Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the degree of risk and level of surveillance.

On the basis, primarily, of animal experiments, concern has been expressed by at least one classification body that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment.

Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.

Ytterbium is a member of the so-called heavy-group (the yttriums) of the rare earths (or lanthanoids). No occupational diseases or cases of poisoning in workers producing rare earth elements have been described.

Lanthanoids entering the human body due to exposure to various industrial processes can affect metabolic processes. Trivalent lanthanoid ions, especially lanthanum 3+ and gadolinium 3+, can interfere with calcium channels in human and animal cells. Lanthanoids can also alter or even inhibit the action of various enzymes. Lanthanoid ions found in neurons can regulate synaptic transmission, as well as block some receptors (for example, glutamate receptors). Lanthanoids target the liver causing fatty liver degeneration and a decrease in liver glycogen and blood glucose levels.

Lanthanoids because of their high density can produce significant abnormalities in a chest X-ray. Lanthanoids are generally not fibrogenic and lesions typically have little or no clinical importance. Occasional cases of suspected pneumoconiosis have however been reported. The toxicity of all elements in the yttrium group has been investigated in workers and animals alike. Effects on peripheral blood including a decrease haemoglobin and erythrocyte content and changes in the leucocyte formula have been recorded. Animal lungs show productive inflammation and a tendency to develop nodular or diffuse sclerosis following administration by intratracheal injection. The main risks to workers involved in the production of rare earths are due to dust inhalation.

Chronic

Based on the available toxicity data, the rare earth chlorides appear to have moderate acute and chronic toxicity. However these substances cause severe eye irritation and severe irritation in abraded skin. They are poorly absorbed by the gastrointestinal tract and by unbroken skin but slight liver damage has been demonstrated in subchronic oral toxicity studies at high doses. The literature indicates that chronic inhalation exposure to the rare earth chlorides may cause pneumoconiosis in humans. There are no indications of carcinogenicity in the rare earth chlorides. Mutagenicity studies on these substances have mixed results, but are predominantly negative.

* IUPAC currently recommends the name lanthanoid rather than lanthanide, as the suffix "-ide" generally indicates negative ions whereas the suffix "-oid" indicates similarity to one of the members of the containing family of elements. In the older literature, the name "lanthanon" was often used.

Persons with a history of asthma or other respiratory problems or are known to be sensitised, should not be engaged in any work involving the handling of isocyanates.

The chemistry of reaction of isocyanates, as evidenced by MDI, in biological milieu is such that in the event of a true exposure of small MDI doses to the mouth, reactions will commence at once with biological macromolecules in the buccal region and will continue along the digestive tract prior to reaching the stomach. Reaction products will be a variety of polyureas and macromolecular conjugates with for example mucus, proteins and cell components.

This is corroborated by the results from an MDI inhalation study. Following an inhalation exposure of rats to radiolabelled MDI, 79% of the dose was excreted in faeces. The faecal excretion in these animals was considered entirely due to ingestion of radioactivity from grooming and ingestion of deposited material from the nasopharangeal region via the mucociliary escalator, i.e. not following systemic absorption. The faecal radioactivity was tentatively identified as mixed molecular weight polyureas derived from MDI. Diamine was not present. Thus, for MDI and diisocyanates in general the oral gavage dosing route is inappropriate for toxicological studies and risk assessment.

It is expected that oral gavage dosing will result in a similar outcome to that produced by TDI or MDI, that is (1) reaction with stomach contents and (2) polymerization to solid polyureas.

- Reaction with stomach contents is very plausibly described in case reports of accidental ingestion of polymeric MDI based glue in domestic
 animals. Extensive polymerization and CO2 liberation resulting in an expansion of the gastric content is described in the stomach, without
 apparent acute chemical toxicity
- Polyurea formation in organic and aqueous phases has been described. In this generally accepted chemistry of hydrolysis of an isocyanate the initially produced carbamate decarboxylates to an amine which. The amine, as a reactive intermediate, then reacts very readily with the present isocyanate to produce a solid and inert polyurea. This urea formation acts as a pH buffer in the stomach, thus promoting transformation of the disocyanate into polyurea, even under the acidic conditions.

At the resorbtive tissues in the small intestine, these high molecular reaction products are likely to be of very low bioavailability, which is substantiated by the absence of systemic toxicity in acute oral bioassays with rats at the OECD limit dose (LC50-2 g/kg bw).

The respiratory tract may be regarded as the main entry for systemically available isocyanates as evidenced following MDI.exposures.

A detailed summary on urinary, plasma and in vitro metabolite studies is provided below. Taken together, all available studies provide convincing evidence that MDI-protein adduct and MDI-metabolite formation proceeds:

- via formation of a labile isocyanate glutathione (GSH)-adduct,
- then transfer to a more stable adduct with larger proteins, and
- without formation of free MDA. MDA reported as a metabolite is actually formed by analytical workup procedures (strong acid or base hydrolysis) and is not an identified metabolite in urine or blood

Sensitisation may give severe responses to very low levels of exposure, in situations where exposure may occur.

Orale Automate Orale Occupants	TOXICITY	IRRITATION
Stela Automix, Stela Capsule	Not Available	Not Available
	TOXICITY	IRRITATION
diurethane dimethacrylate	dermal (rat) LD50: >2000 mg/kg ^[1]	Eye: no adverse effect observed (not irritating) ^[1]

 Version No: 2.1
 Page 10 of 16
 Issue Date: 05/07/2022

 Print Date: 15/07/2022
 Print Date: 15/07/2022

Stela Automix, Stela Capsule

	Oral (Rat) LD50; >2000 mg/kg ^[2]	Skin: no adverse effect observed (not irritating) ^[1]
glycerol dimethacrylate	TOXICITY Not Available	IRRITATION Not Available
ytterbium(III) fluoride	TOXICITY Oral (Rat) LD50; >2000 mg/kg ^[1]	IRRITATION Skin: no adverse effect observed (not irritating) ^[1]
10-methacryloyloxydecyl dihydrogen phosphate	TOXICITY Not Available	IRRITATION Not Available
Legend:	Nalue obtained from Europe ECHA Registered Substances - Acute to specified data extracted from RTECS - Register of Toxic Effect of chemic	

* Possible carcinogen; possible sensitizer; possible irreversible effects * Polysciences MSDS The skin sensitising potential of the test substance was investigated in a Local Lymph Node Assay (LLNA) in mice according to OECD Guideline 429 and in compliance with GLP (Vogel, 2009). The highest technically achievable test substance concentration was 50% (w/w) in dimethylformamide. To determine the highest non-irritant test concentration, a pre-test was performed in two animals. Two mice were treated with concentrations of 25 and 50% each on three consecutive days. No signs of irritation or systemic toxicity were observed at the tested concentrations. In the main study, four female CBA/CaOlaHsd mice per test group were treated with the test substance at concentrations of 10, 25 and 50% (w/w) in dimethylformamide or with vehicle alone for three consecutive days by open application on the ears (25 µL/ear). Three days after the last exposure, all animals were injected with 3H-methyl thymidine and approximately after five hours the draining (auricular) lymph nodes were excised and pooled for each test group. After precipitating the DNA of the lymph node cells, radioactivity measurements were performed. Treatment with test substance concentrations of 10, 25 and 50% (w/w) in dimethylformamide resulted in DPM values per lymph node of 1266.3, 1363.5 and 3562.1, respectively. The SI values calculated for the substance concentrations 10, 25 and 50% were 1.58, 1.70 and 4.44, respectively. The EC3 value was calculated to be 36.9%. Based on the results, the test substance was regarded as a skin sensitizer under the conditions of the test. Repeat Dose Toxicity: NOAEL = 100 mg/kg bw/day for males NOAEL = 300 mg/kg bw/day for females The lowest observed adverse effect level (LOAEL) in male animals is 300 mg/kg bw/day. According to Annex I of Regulation (EC) No 1272/2008 classification as STOT RE Category 2 is applicable, when significant toxic effects observed in a 90-day repeated-dose study conducted in experimental animals are seen to occur within the guidance value ranges of 10 < C = 100 mg/kg bw/day. These guidance values can be used as a basis to extrapolate equivalent guidance values for toxicity studies of greater or lesser duration, using dose/exposure time extrapolation similar to Habers rule for inhalation, which states essentially that the effective dose is directly proportional to the exposure concentration and the duration of exposure. The assessment shall be done on a case-by- case basis; for a 28-day study the guidance value is increased by a factor of three. The available repeated dose toxicity study was conducted in combination with the reproductive/developmental toxicity screening test. Male animals were exposed to the test substance for 56 days. Thus the guidance value is increased by a factor of 1.6 leading to a guidance value range of 16 < C = 160 mg/kg bw/day for a classification as STOT RE Category 2. The LOAEL of 300 mg/kg/bw/day in the present study is above the guidance value for a classification with regard to repeated exposure. Thus, the available data on oral repeated dose toxicity do not meet the criteria for classification according to Regulation (EC) No 1272/2008, and is therefore conclusive but not sufficient for classification. Genetic toxicity: The available data on genetic toxicity are not sufficient for classification according to Regulation (EC) No 1272/2008. Gene mutation in bacteria A bacterial gene mutation assay with the test substance was performed in accordance with OECD Guideline 471 and in compliance with GLP (Paulus, 2009). In two independent experiments, the Salmonella typhimurium strains TA 97a, TA 98, TA 100, TA 102 and TA 1535 were exposed to the test substance dissolved in DMSO using either the preincubation or the plate incorporation method. Test substance concentrations of 50, 150, 500, 1501 and 5004 ug/plate were selected for the plate incorporation test with and without metabolic activation. In the second experiment, 312, 624, 1247, 2493 and 4986 µg/plate were selected for the preincubation method with and without metabolic activation. No signs of cytotoxicity were observed up to and including the limit concentration. Up to 5000 µg/plate, the test substance did not induce an increase in the mutation frequency of the tester strains in the presence and absence of a metabolic activation system. The determined vehicle values for the spontaneous revertants of the controls and all positive control values were within the range of historical data. Under the conditions of this experiment, the test substance did not show mutagenicity in the selected S, typhimurium strains in the presence and absence of metabolic activation. In vitro cytogenicity An in vitro micronucleus assay was performed with the test substance (Schweikl, 2001). In two independent experiments, Chinese hamster lung fibroblasts were exposed to the test substance dissolved in DMSO at concentrations of 11.75, 23.5, 35.25 µg/mL for 24 h in the absence of metabolic activation. Cytotoxicity of the test substance was observed and the TC50 value was assessed to be 24 µg/mL. At cytotoxic concentration levels of the test substance (= 24 µg/mL) the numbers of micronuclei were slightly increased in the absence of metabolic activation. Ethyl methanesulphonate was used as positive control and produced a distinct increase in micronuclei frequency indicating that the test conditions were adequate. Under the conditions of this experiment, the potential of the test substance to induce micronuclei is equivocal. In vitro mutagenicity in mammalian cells An in vitro HPRT assay was performed with the test substance (Schweikl, 1998). In three replicate cultures Chinese hamster lung fibroblasts were exposed to the test substance dissolved in DMSO at concentrations of 11.75, 23.5, 35.25 µg/mL for 24 h in the absence of metabolic activation. Cytotoxicity of the test substance was observed at concentrations = 23.5 µg/mL. No mutagenic activity of UDMA was detected. Ethyl methanesulphonate was used as positive control and produced a distinct increase in mutant frequency indicating that the test conditions were adequate. Thus, under the conditions of this experiment, the test substance did not show mutagenicity in V79 cells without metabolic activation. Due to the positive result in the in vitro micronucleus test without metabolic activation at cytotoxic concentrations a micronucleus test in vivo should be conducted to conclude on genotoxic potential of the test substance. Reproductive toxicity: The available data on toxicity to reproduction do not meet the criteria for classification according to Regulation (EC) 1272/2008, and are therefore conclusive but not sufficient for classification. reproductive toxicity: NOAEL >= 1000 mg/kg bw/day for males and females of the parental generation systemic toxicity: NOAEL = 100 mg/kg bw/day for males and 300 mg/kg bw/day for females of the parental generation A reliable sub-acute study regarding reproductive/developmental toxicity is available for the test substance. The potential reproductive or developmental toxicity of the test substance was assessed in a sub-acute combined repeated dose toxicity study with the reproductive/developmental toxicity screening test in Hsd.Han: Wistar rats performed according to OECD Guideline 422 and in compliance with GLP. Three groups of 12 male and 12 female rats received the test substance in polyethylene glycol as vehicle at doses of 100, 300 or 600 mg/kg bw/day orally via gavage at concentrations of 0, 25, 75 and 150 mg/mL corresponding to a 4 mL/kg bw dosing volume. A control group of 12 animals/sex received the vehicle only. In addition, 5 animals/sex were added to the control and high dose group to assess the reversibility of any effects observed at the high dose level (recovery group). All animals of the parental generation were dosed prior to mating (14 days) and throughout mating. In addition, males received the test item or vehicle after mating up to the day before necropsy (altogether for 56 days). Females were additionally exposed through the gestation period and up to lactation days 13 - 21, i.e. up to the day before necropsy (altogether for 56, 57 or 64 days). Observations included mortality, clinical signs, body weight, food consumption, mating, pregnancy and delivery proce lactation as well as development of offspring. The dams were allowed to litter, and rear their offspring up to day 13 post-partum. Litters were weighed and offspring were observed for possible abnormalities and were euthanized on post-natal day 13 or shortly thereafter. Blood samples

were collected for determination of serum levels of thyroid hormones (T4) from all pups per litter at termination on post-natal day 13. No adverse effect on mortality, clinical signs, body weight or necropsy findings were detected in the offspring terminated as scheduled. Thyroid homone levels (T4) in pups on post-natal day 13 were not affected. The anogenital distance (male and female) or nipple retention (male) was not affected due to treatment with the test substance. For the parental animals pale livers and histopathological changes in the liver (hepatic lipidosis) were observed at 300 mg/kg bw/day for males and 1000 mg/kg bw/day for females. Thus, under the conditions of this study, the NOAEL of the test substance for systemic toxicity of the parental generation following oral administration via gavage for 56 days is 100 mg/kg bw/day in male Wistar rats. The corresponding NOAEL in female Wistar rats following oral administration via gavage for 56, 57 or 64 days is

DIURETHANE DIMETHACRYLATE

Version No: 2.1 Page 11 of 16 Issue Date: 05/07/2022
Print Date: 15/07/2022

Stela Automix, Stela Capsule

300 mg/kg bw/day. The corresponding NOAEL for the offspring is 1000 mg/kg bw/day. * REACh Dossier The material may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis **GLYCEROL DIMETHACRYLATE** The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling the epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis. Symptoms of acute lanthanide toxicity in rats are immediate defecation, writhing, ataxia (the inability to coordinate voluntary muscular movement), sedation, laboured respiration and reduced activity. Death is due mainly to respiratory and cardiac failure. The rare earths exhibit low toxicity following ingestion but may be toxic by the intraperitoneal route and mildly toxic when administered by the subcutaneous route. The production of skin and lung granulomas, following exposure, may also occur. for typical lanthanides: The symptoms of toxicity of the rare earth elements include writhing, ataxia, labored respiration, walking on the toes with arched back and sedation. The rare earth elements exhibit low toxicity by ingestion exposure. However, the intraperitoneal route may be highly toxic while the subcutaneous route is poison to moderately toxic. The production of skin and lung granulomas after exposure to them requires extensive YTTERBIUM(III) FLUORIDE protection to prevent such exposure. Chronic Inhalation Toxicity: An accumulation of insoluble lanthanide particles has been observed in the respiratory tract of humans following chronic occupational exposure and in rodents following chronic exposure to a similar lanthanide cerium oxide. Lymphoid hyperplasia in the bronchial lymph nodes was the critical inhalation health effect identified by the USEPA in a 2008 toxicological review of cerium oxide. Developmental/Reproductive Toxicity: Lanthanum carbonate, did not affect fertility or produce any harm to the fetus in a rat study. Mutagenicity: Cerium oxide, was negative in the Ames bacterial mutagenic test using bacterial strains TA135, TA1537, TA98, TA100, TA102, and WP2uvrA., and in the mouse in vivo micronucleus assay. Carcinogenicity: Lanthanum carbonate, was not carcinogenic in a two-year oral rat study. Not assessed by IARC, NTP, or USEPA. DIURETHANE Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test, oral (OECD 422), rat: DIMETHACRYLATE The following information refers to contact allergens as a group and may not be specific to this product. Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact DIURETHANE eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, **DIMETHACRYLATE &** involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the 10-METHACRYLOYLOXYDECYL distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely DIHYDROGEN PHOSPHATE distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested. Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main DIURETHANE criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent **DIMETHACRYLATE &** asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a **GLYCEROL DIMETHACRYLATE** reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of & YTTERBIUM(III) FLUORIDE & minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates 10-METHACRYLOYLOXYDECYL related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that DIHYDROGEN PHOSPHATE occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production. UV (ultraviolet)/ EB (electron beam) acrylates are generally of low toxicity UV/EB acrylates are divided into two groups; "stenomeric" and "eurymeric" acrylates. The first group consists of well-defined acrylates which can be described by a simple idealised chemical; they are low molecular weight species with a very narrow weight distribution profile. The eurymeric acrylates cannot be described by an idealised structure and may differ fundamentally between various suppliers; they are of relatively high molecular weigh and possess a wide weight distribution. DIURETHANE Stenomeric acrylates are usually more hazardous than the eurymeric substances. Stenomeric acrylates are also well defined which allows **DIMETHACRYLATE &** comparison and exchange of toxicity data - this allows more accurate classification. GLYCEROL DIMETHACRYLATE The stenomerics cannot be classified as a group; they exhibit substantial variation. Based on the available oncogenicity data and without a better understanding of the carcinogenic mechanism the Health and Environmental Review Division (HERD), Office of Toxic Substances (OTS), of the US EPA previously concluded that all chemicals that contain the acrylate or methacrylate moiety (CH2=CHCOO or CH2=C(CH3)COO) should be considered to be a carcinogenic hazard unless shown otherwise by adequate testing This position has now been revised and acrylates and methacrylates are no longer de facto carcinogens. DIURETHANE **DIMETHACRYLATE &** Where no "official" classification for acrylates and methacrylates exists, there has been cautious attempts to create classifications in the **GLYCEROL DIMETHACRYLATE** absence of contrary evidence. For example Monalkyl or monoarylesters of acrylic acids should be classified as R36/37/38 and R51/53 10-METHACRYLOYLOXYDECYL Monoalkyl or monoaryl esters of methacrylic acid should be classified as R36/37/38 **DIHYDROGEN PHOSPHATE** YTTERBIUM(III) FLUORIDE & 10-METHACRYLOYLOXYDECYL No significant acute toxicological data identified in literature search. DIHYDROGEN PHOSPHATE

			1
Acute Toxicity	X	Carcinogenicity	×
Skin Irritation/Corrosion	✓	Reproductivity	×
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	✓
Respiratory or Skin sensitisation	✓	STOT - Repeated Exposure	×
Mutagenicity	×	Aspiration Hazard	×

Legend:

X - Data either not available or does not fill the criteria for classification

— Data available to make classification

11.2 Information on other hazards

11.2.1. Endocrine Disruption Properties

Not Available

Version No: 2.1 Page 12 of 16 Issue Date: 05/07/2022 Print Date: 15/07/2022

Stela Automix, Stela Capsule

Stela Automix, Stela Capsule	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	72h	Algae or other aquatic plants	0.21mg/l	2
diurethane dimethacrylate	EC50	72h	Algae or other aquatic plants	>0.68mg/l	2
didi etilalie dililetilaci ylate	EC50	48h	Crustacea	>1.2mg/l	2
	LC50	96h	Fish	10.1mg/l	Not Availab
glycerol dimethacrylate	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Availab
	Endpoint	Test Duration (hr)	Species	Value	Source
ytterbium(III) fluoride	NOEC(ECx)	48h	Crustacea	0.52mg/l	2
	EC50	48h	Crustacea	>0.52mg/l	2
10-methacryloyloxydecyl dihydrogen phosphate	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Availab
Legend:			IA Registered Substances - Ecotoxicological Informat Aquatic Hazard Assessment Data 6. NITE (Japan) - B		

DO NOT discharge into sewer or waterways.

12.2. Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
glycerol dimethacrylate	LOW	LOW

12.3. Bioaccumulative potential

Ingredient	Bioaccumulation	
glycerol dimethacrylate	LOW (LogKOW = 1.1616)	

12.4. Mobility in soil

Ingredient	Mobility
glycerol dimethacrylate	LOW (KOC = 10)

12.5. Results of PBT and vPvB assessment

	Р	В	Т	
Relevant available data	Not Available	Not Available	Not Available	
PBT	X	×	X	
vPvB	×	×	×	
PBT Criteria fulfilled?				
vPvB	No			

12.6. Endocrine Disruption Properties

Not Available

12.7. Other adverse effects

Not Available

SECTION 13 Disposal considerations

13.1. Waste treatment methods

- ▶ Containers may still present a chemical hazard/ danger when empty.
- ▶ Return to supplier for reuse/ recycling if possible. Otherwise:

If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same Product / Packaging disposal product, then puncture containers, to prevent re-use, and bury at an authorised landfill.

- - ▶ Where possible retain label warnings and SDS and observe all notices pertaining to the product. DO NOT allow wash water from cleaning or process equipment to enter drains.
 - It may be necessary to collect all wash water for treatment before disposal.

Version No: 2.1 Page 13 of 16 Issue Date: 05/07/2022 Print Date: 15/07/2022

Stela Automix, Stela Capsule

▶ In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first. Where in doubt contact the responsible authority. ► DO NOT recycle spilled material. ▶ Consult State Land Waste Management Authority for disposal. ▶ Neutralise spill material carefully and decontaminate empty containers and spill residues with 10% ammonia solution plus detergent or a proprietary decontaminant prior to disposal. DO NOT seal or stopper drums being decontaminated as CO2 gas is generated and may pressurise containers. ▶ Puncture containers to prevent re-use. ▶ Bury or incinerate residues at an approved site.

SECTION 14 Transport information

Waste treatment options

Sewage disposal options

Labels Required

Marine Pollutant

Land transport (ADR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Not Available

Not Available

Not Applicable		
Not Applicable		
Class Not Applicable Subrisk Not Applicable		
Not Applicable		
Not Applicable		
Hazard identification (Kemler)	Not Applicable	
Classification code	Not Applicable	
Hazard Label	Not Applicable	
Special provisions	Not Applicable	
Limited quantity	Not Applicable	
Tunnel Restriction Code	Not Applicable	
	Class Not Applicable Subrisk Not Applicable Not Applicable Not Applicable Hazard identification (Kemler) Classification code Hazard Label Special provisions Limited quantity	

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

	•			
14.1. UN number	Not Applicable			
14.2. UN proper shipping name	Not Applicable			
	ICAO/IATA Class	Not Applicable		
14.3. Transport hazard class(es)	ICAO / IATA Subrisk Not Applicable			
,	ERG Code Not Applicable			
14.4. Packing group	Not Applicable			
14.5. Environmental hazard	Not Applicable			
	Special provisions		Not Applicable	
	Cargo Only Packing Instructions		Not Applicable	
	Cargo Only Maximum Qty / Pack		Not Applicable	
14.6. Special precautions for user	Passenger and Cargo Packing Instructions		Not Applicable	
450	Passenger and Cargo Maximum Qty / Pack		Not Applicable	
	Passenger and Cargo Limited Quantity Packing Instructions		Not Applicable	
	Passenger and Cargo Limited Maximum Qty / Pack		Not Applicable	

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.1. UN number	Not Applicable		
14.2. UN proper shipping name	Not Applicable		
14.3. Transport hazard class(es)	IMDG Class Not Applicable IMDG Subrisk Not Applicable		
14.4. Packing group	Not Applicable		
14.5. Environmental hazard	Not Applicable		
14.6. Special precautions for user	EMS Number Not Applicable Special provisions Not Applicable		

Version No: 2.1 Page **14** of **16** Issue Date: 05/07/2022

Print Date: 15/07/2022 Stela Automix, Stela Capsule

Limited Quantities Not Applicable

Inland waterways transport (ADN): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.1. UN number	Not Applicable		
14.2. UN proper shipping name	Not Applicable		
14.3. Transport hazard class(es)	Not Applicable Not Applicable		
14.4. Packing group	Not Applicable		
14.5. Environmental hazard	Not Applicable		
14.6. Special precautions for user	Classification code Special provisions	Not Applicable Not Applicable	
	Limited quantity	Not Applicable	
	Equipment required	Not Applicable	
	Fire cones number	Not Applicable	

14.7. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.8. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
diurethane dimethacrylate	Not Available
glycerol dimethacrylate	Not Available
ytterbium(III) fluoride	Not Available
10-methacryloyloxydecyl dihydrogen phosphate	Not Available

14.9. Transport in bulk in accordance with the ICG Code

Product name	Ship Type
diurethane dimethacrylate	Not Available
glycerol dimethacrylate	Not Available
ytterbium(III) fluoride	Not Available
10-methacryloyloxydecyl dihydrogen phosphate	Not Available

SECTION 15 Regulatory information

15.1. Safety, health and environmental regulations / legislation specific for the substance or mixture

diurethane dimethacrylate is found on the following regulatory lists

Europe EC Inventory European Union - European Inventory of Existing Commercial Chemical Substances (EINECS)

European Union (EU) Regulation (EC) No 1272/2008 on Classification, Labelling and Packaging of Substances and Mixtures - Annex VI

glycerol dimethacrylate is found on the following regulatory lists

Europe EC Inventory

European Union - European Inventory of Existing Commercial Chemical Substances (EINECS)

ytterbium(III) fluoride is found on the following regulatory lists

EU Consolidated List of Indicative Occupational Exposure Limit Values (IOELVs)

Europe EC Inventory

European Union - European Inventory of Existing Commercial Chemical Substances (EINECS)

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

10-methacryloyloxydecyl dihydrogen phosphate is found on the following regulatory lists

Not Applicable

This safety data sheet is in compliance with the following EU legislation and its adaptations - as far as applicable -: Directives 98/24/EC, - 92/85/EEC, - 94/33/EC, - 2008/98/EC, -2010/75/EU; Commission Regulation (EU) 2020/878; Regulation (EC) No 1272/2008 as updated through ATPs.

15.2. Chemical safety assessment

No Chemical Safety Assessment has been carried out for this substance/mixture by the supplier.

ECHA SUMMARY

Ingredient	CAS number	Index No		ECHA Dossie	r
diurethane dimethacrylate	72869-86-4	616-087-00-9		Not Available	
Harmonisation (C&L Inventory)	Hazard Class and Category Code(s)		Pictograms Signal (Code(s)	Word	Hazard Statement Code(s)

Version No: 2.1 Page 15 of 16 Issue Date: 05/07/2022 Print Date: 15/07/2022

Stela Automix, Stela Capsule

Harmonisation (C&L Hazard Class and Category Code(s) Pictograms Signal Word Code(s) Hazard Statement Code(s) Inventory) 1 Aquatic Chronic 3 H412 2 Aquatic Chronic 3 H412 1 Skin Sens. 1; Eye Irrit. 2; Aquatic Chronic 2 GHS09; GHS07; Wng H317; H319; H411 2 Skin Sens. 1; Eye Irrit. 2; Aquatic Chronic 2 GHS09; GHS07; Wng H317; H319; H411 H317 Skin Sens. 1 Wng 1 Skin Sens. 1B; Aquatic Chronic 2; Skin Irrit. 2; Eye Irrit. 2; STOT SE H317; H411; H315; H319; 2

Harmonisation Code 1 = The most prevalent classification. Harmonisation Code 2 = The most severe classification.

Ingredient	CAS number	Index No	ECHA Dossier
glycerol dimethacrylate	1830-78-0	Not Available	Not Available

GHS09; GHS07; Wng

Harmonisation (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Skin Irrit. 2; Eye Irrit. 2; STOT SE 3	GHS07; Wng	H315; H319; H335
2	Skin Irrit. 2; Eye Irrit. 2; STOT SE 3; Skin Sens. 1	GHS07; Wng	H315; H319; H335; H317

Harmonisation Code 1 = The most prevalent classification. Harmonisation Code 2 = The most severe classification.

Ingredient	CAS number	Index No	ECHA Dossier
ytterbium(III) fluoride	13760-80-0	Not Available	Not Available

Harmonisation (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Skin Irrit. 2; Eye Irrit. 2; STOT SE 3	GHS07; Wng	H315; H319; H335
2	Skin Irrit. 2; Eye Irrit. 2; STOT SE 3; Acute Tox. 3; Acute Tox. 3; Acute Tox. 3; Aquatic Chronic 4	GHS06; Dgr	H315; H319; H335; H301; H311; H331; H413

Harmonisation Code 1 = The most prevalent classification. Harmonisation Code 2 = The most severe classification.

Ingredient	CAS number	Index No	ECHA Dossier
10-methacryloyloxydecyl dihydrogen phosphate	85590-00-7	Not Available	Not Available

Harmonisation (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Skin Irrit. 2; Eye Irrit. 2; STOT SE 3	GHS05; Dgr	H314; H319; H335
2	Skin Irrit. 2; Eye Irrit. 2; STOT SE 3	GHS05; Dgr	H314; H319; H335

 $Harmonisation \ Code \ 1 = The \ most \ prevalent \ classification. \ Harmonisation \ Code \ 2 = The \ most \ severe \ classification.$

National Inventory Status

National Inventory	Status	
Australia - AIIC / Australia Non-Industrial Use	No (glycerol dimethacrylate; ytterbium(III) fluoride; 10-methacryloyloxydecyl dihydrogen phosphate)	
Canada - DSL	No (diurethane dimethacrylate; glycerol dimethacrylate; ytterbium(III) fluoride; 10-methacryloyloxydecyl dihydrogen phosphate)	
Canada - NDSL	No (10-methacryloyloxydecyl dihydrogen phosphate)	
China - IECSC	No (10-methacryloyloxydecyl dihydrogen phosphate)	
Europe - EINEC / ELINCS / NLP	No (10-methacryloyloxydecyl dihydrogen phosphate)	
Japan - ENCS	No (diurethane dimethacrylate; 10-methacryloyloxydecyl dihydrogen phosphate)	
Korea - KECI	No (10-methacryloyloxydecyl dihydrogen phosphate)	
New Zealand - NZIoC	No (10-methacryloyloxydecyl dihydrogen phosphate)	
Philippines - PICCS	No (glycerol dimethacrylate; ytterbium(III) fluoride; 10-methacryloyloxydecyl dihydrogen phosphate)	
USA - TSCA	No (10-methacryloyloxydecyl dihydrogen phosphate)	
Taiwan - TCSI	No (10-methacryloyloxydecyl dihydrogen phosphate)	
Mexico - INSQ	No (diurethane dimethacrylate; glycerol dimethacrylate; ytterbium(III) fluoride; 10-methacryloyloxydecyl dihydrogen phosphate)	
Vietnam - NCI	No (ytterbium(III) fluoride; 10-methacryloyloxydecyl dihydrogen phosphate)	
Russia - FBEPH	No (diurethane dimethacrylate; glycerol dimethacrylate; 10-methacryloyloxydecyl dihydrogen phosphate)	
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.	

SECTION 16 Other information

Revision Date	05/07/2022
Initial Date	05/07/2022

Version No: 2.1 Page **16** of **16** Issue Date: 05/07/2022

Stela Automix, Stela Capsule

Print Date: 15/07/2022

H301	Toxic if swallowed.
H302+H312+H332	Harmful if swallowed, in contact with skin or if inhaled.
H311	Toxic in contact with skin.
H314	Causes severe skin burns and eye damage.
H331	Toxic if inhaled.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.
H413	May cause long lasting harmful effects to aquatic life.

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by SDI Limited using available literature

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

For detailed advice on Personal Protective Equipment, refer to the following EU CEN Standards:

EN 166 Personal eye-protection

EN 340 Protective clothing

EN 374 Protective gloves against chemicals and micro-organisms

EN 13832 Footwear protecting against chemicals

EN 133 Respiratory protective devices

Definitions and abbreviations

PC-TWA: Permissible Concentration-Time Weighted Average

PC-STEL: Permissible Concentration-Short Term Exposure Limit

IARC: International Agency for Research on Cancer

ACGIH: American Conference of Governmental Industrial Hygienists

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit,

IDLH: Immediately Dangerous to Life or Health Concentrations

ES: Exposure Standard OSF: Odour Safety Factor

NOAEL :No Observed Adverse Effect Level

LOAEL: Lowest Observed Adverse Effect Level

TLV: Threshold Limit Value

LOD: Limit Of Detection OTV: Odour Threshold Value

BCF: BioConcentration Factors

BEI: Biological Exposure Index

AIIC: Australian Inventory of Industrial Chemicals

DSL: Domestic Substances List NDSL: Non-Domestic Substances List

IECSC: Inventory of Existing Chemical Substance in China

EINECS: European INventory of Existing Commercial chemical Substances

ELINCS: European List of Notified Chemical Substances

NLP: No-Longer Polymers

ENCS: Existing and New Chemical Substances Inventory

KECI: Korea Existing Chemicals Inventory

NZIoC: New Zealand Inventory of Chemicals

PICCS: Philippine Inventory of Chemicals and Chemical Substances

TSCA: Toxic Substances Control Act

TCSI: Taiwan Chemical Substance Inventory

INSQ: Inventario Nacional de Sustancias Químicas

NCI: National Chemical Inventory

FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

The information contained in the Safety Data Sheet is based on data considered to be accurate, however, no warranty is expressed or implied regarding the accuracy of the data or the results to be obtained from the use thereof.

Other information:

Prepared by: SDI Limited

3-15 Brunsdon Street, Bayswater Victoria, 3153, Australia

Phone Number: +61 3 8727 7111

Department issuing SDS: Research and Development

Contact: Technical Director